1 Institute of Biomedical Technologies Nizhny Novgorod State Medical Academy, 603950, Nizhny Novgorod, Russia
2 Institute of Applied Physics Russian Academy of Sciences, 603950, Nizhny Novgorod, Russia
3 Federal Research Center ?Crystallography and photonics? Russian Academy of Sciences, 119333, Moscow, Russia
4 Radiation Diagnostics and Therapy Department Nizhny Novgorod State Academy, 603950, Nizhny Novgorod, Russia
tumor oxygenation diffuse optical spectroscopy (DOS) pentoxifylline Pliss’s lymph sarcoma (PLS) Frontiers of Optoelectronics
2017, 10(3): 317
Author Affiliations
Abstract
1 Gude Lab, ACTREC, Tata Memorial Center Kharghar, Navi Mumbai 410210 India
2 Chilakapati Lab, ACTREC, Tata Memorial Center Kharghar, Navi Mumbai 410210 India
Breast cancer is one of the leading causes of cancer-related deaths in a global scenario. In the present study, biochemical changes exerted upon Pentoxifylline (PTX) treatment had been appraised in human breast cancer cells using Raman spectroscopy. There are no clinically approved methods to monitor such therapeutic responses available. The spectral profiling is suggestive of changes in DNA, protein and lipid contents showing a linear relationship with drug dosage. Further, multivariate analysis using principal-component based linear-discriminant-analysis (PC-LDA) was employed for classifying the control and the PTX treated groups. These findings support the feasibility of Raman spectroscopy as an alternate/adjunct label-free, objective method for monitoring drug-induced modifications against breast cancer cells.
Pentoxifylline MDA-MB-231 breast cancer cells Raman spectroscopy spectra multivariate analysis Journal of Innovative Optical Health Sciences
2015, 8(2): 1550004